Growth Metrics

Armata Pharmaceuticals (ARMP) Other Accumulated Expenses (2016 - 2026)

Quarterly results put Other Accumulated Expenses at $372000.0 for Q1 2026, up 10.39% from a year ago — trailing twelve months through Mar 2026 was $372000.0 (up 10.39% YoY), and the annual figure for FY2025 was $487000.0, down 7.94%.

Armata Pharmaceuticals has reported Other Accumulated Expenses over the past 6 years, most recently at $372000.0 for Q1 2026.

  • Other Accumulated Expenses reached $372000.0 in Q1 2026 per ARMP's latest filing, down from $487000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $529000.0 in Q4 2024 and bottomed at $124000.0 in Q2 2024.
  • Median Other Accumulated Expenses over the past 4 years was $429500.0 (2025), compared with a mean of $384700.0.
  • Peak annual rise in Other Accumulated Expenses hit 10.48% in 2025, while the deepest fall reached 7.94% in 2025.
  • Over 4 years, Other Accumulated Expenses stood at $523000.0 in 2023, then rose by 1.15% to $529000.0 in 2024, then decreased by 7.94% to $487000.0 in 2025, then dropped by 23.61% to $372000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for ARMP at $372000.0 in Q1 2026, $487000.0 in Q4 2025, and $503000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 372,000.00
Dec 31, 2025 487,000.00
Sep 30, 2025 503,000.00
Jun 30, 2025 137,000.00
Mar 31, 2025 337,000.00
Dec 31, 2024 529,000.00
Sep 30, 2024 513,000.00
Jun 30, 2024 124,000.00
Mar 31, 2024 322,000.00
Dec 31, 2023 523,000.00
Sep 30, 2017 20,000.00
Jun 30, 2017 408,000.00
Mar 31, 2017 161,000.00
Dec 31, 2016 185,000.00
Sep 30, 2016 15,000.00
Jun 30, 2016 15,000.00